|Mr. Michael H. Tardugno||Exec. Chairman, Pres & CEO||786.91k||N/A||1951|
|Mr. Jeffrey W. Church CPA, CPA||CFO, Exec. VP & Corp. Sec.||455.92k||N/A||1957|
|Dr. Khursheed Anwer||Exec. VP & Chief Scientific Officer||409.32k||N/A||1960|
|Dr. Nicholas Borys||Exec. VP & Chief Medical Officer||505.98k||N/A||1959|
|Mr. Timothy J. Tumminello||Chief Accounting Officer & Controller||N/A||N/A||1958|
|Ms. Marianne M. Lambertson||VP of Communications & Investor Relations||N/A||N/A||N/A|
Celsion Corporation, an integrated development clinical stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Celsion Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.